Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $44.83 Consensus Target Price from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $44.8333.

AVTX has been the topic of several research analyst reports. Wolfe Research initiated coverage on Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective on the stock. HC Wainwright boosted their price objective on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Citizens Jmp initiated coverage on Avalo Therapeutics in a report on Monday, April 6th. They issued an “outperform” rating and a $52.00 price objective on the stock. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen upgraded Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total value of $110,715.22. Following the completion of the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. This trade represents a 48.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $16.15, for a total transaction of $411,695.80. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This represents a 87.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 63,015 shares of company stock valued at $987,326 in the last three months. 4.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Caligan Partners LP purchased a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $10,592,000. Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. Vanguard Group Inc. boosted its position in Avalo Therapeutics by 314.9% in the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after buying an additional 525,696 shares during the period. Millennium Management LLC boosted its position in Avalo Therapeutics by 380.2% in the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after buying an additional 522,548 shares during the period. Finally, Jennison Associates LLC purchased a new position in Avalo Therapeutics in the fourth quarter worth approximately $8,637,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $16.26 on Wednesday. The firm’s 50-day moving average is $15.33 and its two-hundred day moving average is $16.24. Avalo Therapeutics has a 12 month low of $3.39 and a 12 month high of $20.72. The company has a market capitalization of $434.30 million, a PE ratio of -2.84 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of ($0.21) million. Sell-side analysts forecast that Avalo Therapeutics will post -4.04 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.